🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to researchers.

A Global Health Concern

Cases of gonorrhoea are escalating worldwide, with figures suggesting more than 82 million new cases per year. Notably increased rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the face of rising global incidence, escalating drug resistance and the very limited treatment choices currently available.”

Medical experts are deeply concerned about the surge in drug-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Clearance

One new antibiotic, also known as a brand name, was cleared by the US FDA in December for combating gonorrhoea. This STI can lead to serious health problems, including infertility. Experts anticipate that specific application of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This treatment, which is employed against UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to develop it.

“This milestone represents a major breakthrough in the management of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Testing Outcomes and Worldwide Availability

Based on data published in a major medical journal, the new drug cured over nine in ten of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which uses two antibiotics. The trial involved over 900 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the rights to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have voiced optimism. The availability of a single-dose, oral treatment of this kind is hailed as a "game-changer" for managing the epidemic. This is viewed as essential to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea globally.